Detalhe da pesquisa
1.
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Haematologica
; 108(3): 705-716, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226495
2.
Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay.
Ther Drug Monit
; 45(2): 236-244, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36788448
3.
Comparative analytical performance of multiple plasma Aß42 and Aß40 assays and their ability to predict positron emission tomography amyloid positivity.
Alzheimers Dement
; 2022 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35820077
4.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Blood
; 131(13): 1415-1424, 2018 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29348128
5.
Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure.
JHEP Rep
; 3(6): 100355, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34805815